Prevalence and impact of faecal incontinence among individuals with Rome IV irritable bowel syndrome
- PMID: 36914979
- DOI: 10.1111/apt.17465
Prevalence and impact of faecal incontinence among individuals with Rome IV irritable bowel syndrome
Abstract
Background: Little is known about faecal incontinence (FI) in individuals with irritable bowel syndrome (IBS).
Aims: To compare characteristics of people with IBS reporting FI, compared with people with IBS who do not report FI.
Methods: We collected demographic, gastrointestinal and psychological symptoms, healthcare usage, direct healthcare costs, impact on work and activities of daily living, and quality of life data from individuals with Rome IV-defined IBS. We asked participants about FI, assigning presence or absence according to Rome-IV criteria.
Results: Of 752 participants with Rome IV IBS, 202 (26.9%) met Rome IV criteria for FI. Individuals with FI were older (p < 0.001), more likely to have IBS-D (47.0% vs. 39.0%, p = 0.008), and less likely to have attained a university or postgraduate level of education (31.2% vs. 45.6%, p < 0.001), or to have an annual income of ≥£30,000 (18.2% vs. 32.9%, p < 0.001). They were more likely to report urgency (44.6% vs. 19.1%, p < 0.001) as their most troublesome symptom and a greater proportion had severe IBS symptom scores, abnormal depression scores, higher somatic symptom-reporting scores or higher gastrointestinal symptom-specific anxiety scores (p < 0.01 for trend for all analyses). Mean health-related quality of life scores were significantly lower among those with, compared with those without, FI (p < 0.001). Finally, FI was associated with higher IBS-related direct healthcare costs (p = 0.002).
Conclusions: Among individuals with Rome IV IBS, one-in-four repo rted FI according to Rome IV criteria. Physicians should ask patients with IBS about FI routinely.
Keywords: faecal incontinence; irritable bowel syndrome; quality of life.
© 2023 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Comment in
-
Editorial: faecal incontinence is prevalent in IBS, as are effective treatment options!Aliment Pharmacol Ther. 2023 May;57(10):1174-1175. doi: 10.1111/apt.17486. Aliment Pharmacol Ther. 2023. PMID: 37094309 No abstract available.
-
Editorial: faecal incontinence is prevalent in IBS, as are effective treatment options! Authors' reply.Aliment Pharmacol Ther. 2023 May;57(10):1176-1177. doi: 10.1111/apt.17494. Aliment Pharmacol Ther. 2023. PMID: 37094322 No abstract available.
-
Letter: determining priorities for patients with faecal incontinence and irritable bowel syndrome-authors' reply.Aliment Pharmacol Ther. 2023 Jul;58(1):139-140. doi: 10.1111/apt.17571. Aliment Pharmacol Ther. 2023. PMID: 37307551 No abstract available.
-
Letter: determining priorities for patients with faecal incontinence and irritable bowel syndrome.Aliment Pharmacol Ther. 2023 Jul;58(1):137-138. doi: 10.1111/apt.17559. Aliment Pharmacol Ther. 2023. PMID: 37307559 No abstract available.
References
REFERENCES
-
- Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908-17.
-
- Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016;1(2):133-46.
-
- Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393-407.
-
- Staller K, Olen O, Soderling J, Roelstraete B, Törnblom H, Khalili H, et al. Mortality risk in irritable bowel syndrome: results from a Nationwide prospective cohort study. Am J Gastroenterol. 2020;115(5):746-55.
-
- Chang JY, Locke GR 3rd, McNally MA, et al. Impact of functional gastrointestinal disorders on survival in the community. Am J Gastroenterol. 2010;105(4):822-32.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous